Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Diabetes Care|June 12, 2026
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect ProfileLaura M Jacobsen, Dave Cuthbertson, Jamie Felton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 12, 2025
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetesLauren E Higdon, Laura A Cooney, Elisavet Serti, et al.
The Journal of Allergy and Clinical Immunology|April 5, 2021
Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapyMohamed H Shamji, David Larson, Aarif Eifan, et al.
Frontiers in Immunology|December 5, 2022
HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic successKanika Kanchan, Gautam Shankar, Michelle F Huffaker, et al.
The Journal of Allergy and Clinical Immunology|July 17, 2023
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapyMatthew C Altman, R Max Segnitz, David Larson, et al.
Diabetes|June 23, 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell functionS Alice Long, Mary Rieck, Srinath Sanda, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1Jenny E Kanter, Farah Kramer, Shelley Barnhart, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Plos One|November 13, 2020
Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCRFelipe de Jesus Cortez, David Gebhart, Peter V Robinson, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2022
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trialJonathan Corren, David Larson, Matthew C Altman, et al.
Pageof 5